Roiver Score™ for
ORMPOramed Pharmaceuticals Inc.
Based on fundamentals through 12/31/2025.
As of December 31, 2025, Oramed Pharmaceuticals Inc. (ORMP) scores 50/100 (Solid) on the Roiver Score — a transparent quality composite. Its strongest area is profitability; its weakest is stability. The score measures business quality, not timing — it's a signal, not a recommendation.
No black box
Roiver Score is a transparent 0–100 quality composite. Five components, each 0–20: profitability, capital structure, cash quality, valuation, and stability. Inspired by Piotroski's F-Score, Altman's Z-Score, and the Buffett/Munger framework on quality compounders at fair prices. Read the full methodology →
Frequently asked about ORMP
What is ORMP's Roiver Score?
Oramed Pharmaceuticals Inc. scores 50 out of 100 (Solid) as of December 31, 2025, based on fundamentals.
How is the Roiver Score for ORMP calculated?
It sums five 0–20 components — profitability, capital structure, cash quality, valuation, and stability — into a transparent 0–100 composite. The full methodology is published.
Is ORMP a good quality stock?
On quality, ORMP rates "Solid" (50/100). Its strongest driver is profitability and its weakest is stability. Quality is one input to a decision, not a buy/sell call.
Embed on your site
Drop this iframe into a Substack, blog post, or notion page. Updates automatically as fundamentals change.
<iframe src="https://roiver.com/embed/score/ORMP" width="640" height="280" frameborder="0" style="border:0;border-radius:16px;overflow:hidden" loading="lazy"></iframe>
Get ORMP's Score in your inbox
A free weekly digest of quality scores and what changed. No account needed.
Educational use only. Roiver Score is a quality signal, not a recommendation.